Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the ...

Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotechnology company specializing in oncology treatments, announced ...

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement ...

Immuneering said investors agreed to buy roughly 6.3 million shares of its Class A common stock for $3.95 a piece. In lieu of Class A common stock, certain investors will buy pre-funded warrants to ...

Immuneering evaluated both 240mg and 320mg QD as prospective doses for the Phase 2a portion of its Phase 1/2a study. Based on data from this trial, Immuneering selected a candidate RP2D of 320mg QD.

Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior ...

CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has ...

Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to ...